Fischer SK - Search Results

1

Strategies to compare clinical antitherapeutic antibody data when changing assay platforms: a case study.

Qiu ZJ, Ying Y, Lewin-Koh SC, Coleman D, Brignoli S, Hendricks R, Siguenza P, Quarmby V, Fischer SK, Song A. Qiu ZJ, et al. Among authors: fischer sk. Bioanalysis. 2015;7(14):1775-83. doi: 10.4155/bio.15.91. Bioanalysis. 2015. PMID: 26270784

2

Clinical immunogenicity specificity assessments: a platform evaluation.

Peng K, Siradze K, Quarmby V, Fischer SK. Peng K, et al. Among authors: fischer sk. J Pharm Biomed Anal. 2011 Feb 20;54(3):629-35. doi: 10.1016/j.jpba.2010.09.035. Epub 2010 Oct 29. J Pharm Biomed Anal. 2011. PMID: 21035975

3

The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies.

Fischer SK, Yang J, Anand B, Cowan K, Hendricks R, Li J, Nakamura G, Song A. Fischer SK, et al. MAbs. 2012 Sep-Oct;4(5):623-31. doi: 10.4161/mabs.20814. Epub 2012 Jul 23. MAbs. 2012. PMID: 22820463 Free PMC article.

4

Utilizing design of experiments to characterize assay robustness.

Cowan KJ, Erickson R, Sue B, Delarosa R, Gunter B, Coleman DA, Gilbert H, Song A, Fischer SK. Cowan KJ, et al. Among authors: fischer sk. Bioanalysis. 2012 Sep;4(17):2127-39. doi: 10.4155/bio.12.199. Bioanalysis. 2012. PMID: 23013395

5

When assay format matters: a case study on the evaluation of three assay formats to support a clinical pharmacokinetic study.

Peng K, Baker D, Brignoli S, Cabuhat J, Fischer SK. Peng K, et al. Among authors: fischer sk. AAPS J. 2014 Jul;16(4):625-33. doi: 10.1208/s12248-014-9594-7. Epub 2014 Apr 22. AAPS J. 2014. PMID: 24752719 Free PMC article.

6

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.

Peng K, Xu K, Liu L, Hendricks R, Delarosa R, Erickson R, Budha N, Leabman M, Song A, Kaur S, Fischer SK. Peng K, et al. Among authors: fischer sk. MAbs. 2014;6(6):1500-8. doi: 10.4161/mabs.36208. MAbs. 2014. PMID: 25484037 Free PMC article. Clinical Trial.

7

Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics.

Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, Urban K, Ulufatu S, Khawli LA, Prabhu S, Joseph S, Kelley RF. Bumbaca Yadav D, et al. Among authors: fischer sk. J Biol Chem. 2015 Dec 11;290(50):29732-41. doi: 10.1074/jbc.M115.692434. Epub 2015 Oct 21. J Biol Chem. 2015. PMID: 26491012 Free PMC article.

8

Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis.

Schofield C, Fischer SK, Townsend MJ, Mosesova S, Peng K, Setiadi AF, Song A, Baruch A. Schofield C, et al. Among authors: fischer sk. Bioanalysis. 2016 Nov;8(22):2317-2327. doi: 10.4155/bio-2016-0207. Epub 2016 Sep 13. Bioanalysis. 2016. PMID: 27620302

9

Commercial biomarker assays: friend and foe.

Fischer SK, Carrasco-Triguero M, Hong K, Good J, Davancaze T, Nguy T, Li J, Darbonne W, Morimoto A, Zhu Y. Fischer SK, et al. Bioanalysis. 2016 Nov;8(22):2351-2362. doi: 10.4155/bio-2016-0183. Epub 2016 Oct 5. Bioanalysis. 2016. PMID: 27704870

10

Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material.

Fischer SK, Cheu M, Peng K, Lowe J, Araujo J, Murray E, McClintock D, Matthews J, Siguenza P, Song A. Fischer SK, et al. AAPS J. 2017 Jan;19(1):254-263. doi: 10.1208/s12248-016-9998-7. Epub 2016 Oct 13. AAPS J. 2017. PMID: 27739010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters